Thaerapy BV, a pharmaceutical drug product development company, and Resyca BV a joint venture of Medspray Pharma BV and Recipharm AB, that develops soft mist inhalers, signed an exclusive license agreement for Resyca’s soft mist inhaler for the development of a treatment for pulmonary arterial hypertension (PAH).
As part of the agreement, Resyca will receive a signing milestone as well as other milestones for the supply of soft-mist inhalers for Thaerapy’s clinical trials. Additionally, Resyca will receive a royalty based on sales of the drug-device combination once marketed. Resyca and Thaerapy have also agreed on a joint work plan for the comprehensive development program.
